SG11201912813SA - Plasminogen treatment of conditions associated with pai-1 overexpression - Google Patents
Plasminogen treatment of conditions associated with pai-1 overexpressionInfo
- Publication number
- SG11201912813SA SG11201912813SA SG11201912813SA SG11201912813SA SG11201912813SA SG 11201912813S A SG11201912813S A SG 11201912813SA SG 11201912813S A SG11201912813S A SG 11201912813SA SG 11201912813S A SG11201912813S A SG 11201912813SA SG 11201912813S A SG11201912813S A SG 11201912813SA
- Authority
- SG
- Singapore
- Prior art keywords
- pai
- overexpression
- conditions associated
- plasminogen treatment
- plasminogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523901P | 2017-06-23 | 2017-06-23 | |
| PCT/IB2018/000655 WO2018234861A1 (fr) | 2017-06-23 | 2018-06-22 | Traitement par le plasminogène d'affections associées à une surexpression de pai-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201912813SA true SG11201912813SA (en) | 2020-01-30 |
Family
ID=64737041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201912813SA SG11201912813SA (en) | 2017-06-23 | 2018-06-22 | Plasminogen treatment of conditions associated with pai-1 overexpression |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11826404B2 (fr) |
| EP (1) | EP3641888B1 (fr) |
| JP (1) | JP2020524689A (fr) |
| KR (1) | KR20200019217A (fr) |
| CN (1) | CN110831668B (fr) |
| AU (1) | AU2018287316A1 (fr) |
| BR (1) | BR112019027229A2 (fr) |
| CA (1) | CA3068153A1 (fr) |
| CL (1) | CL2019003789A1 (fr) |
| DK (1) | DK3641888T3 (fr) |
| ES (1) | ES2965937T3 (fr) |
| FI (1) | FI3641888T3 (fr) |
| IL (1) | IL271470A (fr) |
| MX (1) | MX2019015741A (fr) |
| RU (1) | RU2020100080A (fr) |
| SG (1) | SG11201912813SA (fr) |
| TW (1) | TW201904990A (fr) |
| WO (1) | WO2018234861A1 (fr) |
| ZA (1) | ZA202000280B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11389515B2 (en) | 2016-12-15 | 2022-07-19 | Talengen International Limited | Method for mitigating heart disease |
| JP7168990B2 (ja) * | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| WO2018107685A1 (fr) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | Procédé de traitement de l'athérosclérose coronaire et de ses complications |
| US20230084586A1 (en) * | 2020-02-06 | 2023-03-16 | Talengen International Limited | Method and drug for preventing and treating multiple sclerosis |
| EP4122488A4 (fr) * | 2020-03-24 | 2023-04-05 | Talengen International Limited | Procédé et médicament pour le traitement de la maladie d'alzheimer |
| WO2021190561A1 (fr) * | 2020-03-24 | 2021-09-30 | 泰伦基国际有限公司 | Procédé et médicament pour le traitement de la maladie de parkinson |
| TW202143999A (zh) * | 2020-03-24 | 2021-12-01 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種促進錯誤摺疊蛋白及其聚集物降解的方法和藥物 |
| CN112174979B (zh) * | 2020-10-27 | 2021-09-07 | 黑龙江中医药大学 | 一种治疗多囊卵巢综合征的药物及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5520912A (en) * | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
| WO2001036351A2 (fr) * | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Antagonistes de l'inhibiteur des activateurs du plasminogène |
| AU3173301A (en) * | 2000-02-11 | 2001-08-20 | European Molecular Biology Laboratory | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity |
| GB0509438D0 (en) | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| CN101573134B (zh) * | 2006-08-28 | 2013-03-06 | 李季男 | 抗感染候选药物 |
| EP2056865B1 (fr) | 2006-08-28 | 2013-12-25 | Omnio Healer AB | Nouvelle cible médicamenteuse de prévention et de traitement des maladies parodontales, favorisant la guérison des lésions parodontales et favorisant l'hygiène buccale |
| ES2770507T3 (es) * | 2013-08-13 | 2020-07-01 | Sanofi Sa | Anticuerpos dirigidos contra el inhibidor de los activadores del plasminógeno de tipo 1 (PAI-1) y usos de los mismos |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| TW201722464A (zh) | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | 用於傷口癒合之纖維蛋白溶酶原給藥方案 |
| JP7168990B2 (ja) * | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| CA3047174A1 (fr) * | 2016-12-15 | 2018-06-21 | Talengen International Limited | Methode de prevention et de traitement d'une fibrose hepatique |
| EP3556386A4 (fr) | 2016-12-15 | 2020-07-08 | Talengen International Limited | Méthode de prévention et de traitement d'une lésion rénale induite par un médicament |
-
2018
- 2018-06-15 TW TW107120839A patent/TW201904990A/zh unknown
- 2018-06-22 EP EP18821458.9A patent/EP3641888B1/fr active Active
- 2018-06-22 JP JP2019570806A patent/JP2020524689A/ja active Pending
- 2018-06-22 SG SG11201912813SA patent/SG11201912813SA/en unknown
- 2018-06-22 KR KR1020207001617A patent/KR20200019217A/ko unknown
- 2018-06-22 WO PCT/IB2018/000655 patent/WO2018234861A1/fr active Application Filing
- 2018-06-22 FI FIEP18821458.9T patent/FI3641888T3/fi active
- 2018-06-22 BR BR112019027229-1A patent/BR112019027229A2/pt not_active Application Discontinuation
- 2018-06-22 CA CA3068153A patent/CA3068153A1/fr active Pending
- 2018-06-22 US US16/625,335 patent/US11826404B2/en active Active
- 2018-06-22 AU AU2018287316A patent/AU2018287316A1/en active Pending
- 2018-06-22 MX MX2019015741A patent/MX2019015741A/es unknown
- 2018-06-22 RU RU2020100080A patent/RU2020100080A/ru unknown
- 2018-06-22 CN CN201880041573.5A patent/CN110831668B/zh active Active
- 2018-06-22 DK DK18821458.9T patent/DK3641888T3/da active
- 2018-06-22 ES ES18821458T patent/ES2965937T3/es active Active
-
2019
- 2019-12-16 IL IL271470A patent/IL271470A/en unknown
- 2019-12-20 CL CL2019003789A patent/CL2019003789A1/es unknown
-
2020
- 2020-01-15 ZA ZA2020/00280A patent/ZA202000280B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3641888B1 (fr) | 2023-10-11 |
| WO2018234861A1 (fr) | 2018-12-27 |
| US20210330761A1 (en) | 2021-10-28 |
| CN110831668A (zh) | 2020-02-21 |
| ES2965937T3 (es) | 2024-04-17 |
| EP3641888A1 (fr) | 2020-04-29 |
| TW201904990A (zh) | 2019-02-01 |
| AU2018287316A1 (en) | 2020-02-06 |
| EP3641888A4 (fr) | 2021-03-10 |
| FI3641888T3 (fi) | 2023-12-19 |
| CN110831668B (zh) | 2024-04-12 |
| DK3641888T3 (da) | 2024-01-02 |
| MX2019015741A (es) | 2020-11-11 |
| ZA202000280B (en) | 2021-08-25 |
| CA3068153A1 (fr) | 2018-12-27 |
| RU2020100080A (ru) | 2021-07-23 |
| CL2019003789A1 (es) | 2020-07-10 |
| KR20200019217A (ko) | 2020-02-21 |
| BR112019027229A2 (pt) | 2020-07-07 |
| RU2020100080A3 (fr) | 2021-11-02 |
| US11826404B2 (en) | 2023-11-28 |
| IL271470A (en) | 2020-01-30 |
| JP2020524689A (ja) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| ZA202000280B (en) | Plasminogen treatment of conditions associated with pai-1 overexpression | |
| ZA202006746B (en) | Methods of treatment | |
| IL271085A (en) | Bacteria to treat disorders | |
| IL261959A (en) | Cancer treatment with tg02 | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| IL268694A (en) | Treatment of schizophrenia | |
| PT3297628T (pt) | Azasetron para uso no tratamento de perda auditiva | |
| ZA201907401B (en) | Treatment of adipocytes | |
| PT3122349T (pt) | Composições para o tratamento da autodigestão | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| HK1255695A1 (zh) | 用於治療眼瞼下垂的組合物和方法 | |
| GB201614415D0 (en) | Enzymes for the treatment of human enterometabolic dysfunction | |
| HUE053089T2 (hu) | Migrén kezelése acetil-leucinnal | |
| HK1252359A1 (zh) | 用於治療疼痛的曲唑酮和加巴噴丁的組合 | |
| IL274748A (en) | Improved cancer treatment | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| SI3781172T1 (sl) | Zdravljenje pljučnice | |
| GB201721278D0 (en) | Compunds and combinations for the treatment of rosacea | |
| HK1250343A1 (zh) | 用於治療聽力損失的司瓊類鈣調神經磷酸酶抑制劑 | |
| GB201706817D0 (en) | Treatment of migraines | |
| GB201704287D0 (en) | Treatment of cancer | |
| GB201703857D0 (en) | Treatment of cancer | |
| GB201702565D0 (en) | Treatment of cancer | |
| SG10201913141UA (en) | Treatment of alphavirus-induced inflammation |